Compare Cassava Sciences Inc (FLNA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs VICI Properties Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while VICI Properties Inc trades at $26.98 (market cap $28.97B). The key difference: VICI Properties Inc is far larger — about 545.2× Cassava Sciences Inc's market cap, and VICI Properties Inc pays a 6.84% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VICI | |
|---|---|---|
Market Cap | $53.14M | $28.97B |
Sector | Health | Real Estate |
52-Week High | $4.64 | $33.93 |
52-Week Low | $1.09 | $25.94 |
Enterprise Value | -$33.43M | $46.19B |
Dividend Yield | — | 6.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
VICI Properties trades at $26.72, up 1.67% with a bearish technical signal despite strong fundamentals including a 76.83% net margin and 11.33% ROE. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed. The company maintains robust cash flow with $2.51B from operations in 2025 and recently completed a Canadian portfolio acquisition, supporting its 6.62% dividend yield.
The stock presents value with a P/E of 9.01 below sector averages, but faces headwinds from tenant concentration risks and technical weakness. Analyst consensus remains strongly bullish with a $30 price target, suggesting 12% upside potential if operational stability persists amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
